Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shenzhen Xinqi Pharmaceutical Technology Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is the only pending action currently on file for the company.
The prosecution is handled by 1 distinct examiner and 1 distinct art unit. This indicates a singular focus for the current portfolio within the USPTO classification system for pharmaceutical technologies.
Sean R Donohue is the busiest examiner with 1 pending office action. As there is only 1 pending action for the company, this examiner is responsible for the full scope of the portfolio's active examination.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18695231 | MICROBUBBLE LYOPHILIZED PREPARATION FOR ULTRASONIC RADIOGRAPHY, CONTRAST AGENT, AND PREPARATION METHOD | DONOHUE, SEAN R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18695231 | MICROBUBBLE LYOPHILIZED PREPARATION FOR ULTRASONIC RADIOGRAPHY, CONTRAST AGENT, AND PREPARATION METHOD | DONOHUE, SEAN R | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18695231 | MICROBUBBLE LYOPHILIZED PREPARATION FOR ULTRASONIC RADIOGRAPHY, CONTRAST AGENT, AND PREPARATION METHOD | DONOHUE, SEAN R | 1618 | §102§103§112 | Non-Final OA | — | Pending | Mar 25, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShenzhen Xinqi Pharmaceutical Technology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sean R Donohue has the most, with 1 of Shenzhen Xinqi Pharmaceutical Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
